Nanotargeted agents: an emerging therapeutic strategy for breast cancer.
Nanomedicine (Lond)
; 14(13): 1771-1786, 2019 07.
Article
em En
| MEDLINE
| ID: mdl-31298065
Breast cancer is the most common female cancer worldwide and represents 12% of all cancer cases. Improvements in survival rates are largely attributed to improved screening and diagnosis. Conventional chemotherapy remains an important treatment option but it is beset with poor cell selectivity, serious side effects and resistance. Nanoparticle drug delivery systems bring promising opportunities to breast cancer treatment. They may improve chemotherapy by targeting drugs to tumors, generating high drug concentrations at tumors providing slow release of the drug, increased drug stability and concomitant reductions in side effects. The nanotechnology-based drug delivery approaches and the current research and application status of nano-targeted agents for breast cancer are discussed in this review to provide a basis for further study on targeted drug delivery systems.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Portadores de Fármacos
/
Sistemas de Liberação de Medicamentos
/
Nanopartículas
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article